
GlaxoSmithKline is readying to move its post-traumatics stress disorder candidate orvepitant into phase II trials, a move being supported by …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

